Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SAN FRANCISCO, CA - Jaguar Health, Inc. (NASDAQ:JAGX) has announced that its subsidiary, Napo Pharmaceuticals, will meet with the U.S. Food and Drug Administration (FDA) in the second quarter of 2025 to discuss the potential approval of crofelemer for the prevention of diarrhea in breast cancer patients. This follows positive results from a subgroup analysis of breast cancer patients in the Phase 3 OnTarget trial, which were presented at the San Antonio Breast Cancer Symposium in December 2024. According to InvestingPro data, the company, currently valued at $3.97 million, has maintained a strong gross profit margin of 83.27% despite facing significant operational challenges.
Crofelemer, a plant-based prescription medicine, has shown promise in preventing diarrhea, a common side effect of targeted cancer therapies that can lead to treatment modifications or discontinuation. The OnTarget study, which did not meet its primary endpoint across all tumor types, found significant results in the subgroup of 183 breast cancer patients out of 287 participants. While the company’s revenue grew by 19.75% in the last twelve months, InvestingPro analysis indicates challenges with cash burn and debt management. For detailed insights, investors can access the comprehensive Pro Research Report, available for over 1,400 US stocks.
The American Cancer Society estimates that there will be 316,950 new cases of breast cancer diagnosed in women in the U.S. in 2025. With a history of invasive breast cancer in approximately 4 million U.S. women as of 2022, the potential approval of crofelemer could address a significant supportive care need for this patient population. InvestingPro indicates the stock is currently undervalued, though investors should note the company’s challenging financial metrics, including negative earnings of -$130.69 per share in the last twelve months.
In addition to the promising results for crofelemer, Napo has also announced the acceptance of a late-breaker abstract for presentation at the Multinational Association of Supportive Care in Cancer (MASCC) 2025 Annual Meeting. This abstract focuses on a screening survey and follow-up focus group about the patient experience with oral mucositis, a painful side effect of cancer treatment.
Jaguar Health and its family of companies are committed to developing treatments for gastrointestinal distress and have previously received FDA approval for crofelemer under the brand name Mytesi® for adults with HIV/AIDS experiencing noninfectious diarrhea. The upcoming FDA meeting and the presentations at the MASCC Annual Meeting represent significant steps in addressing unmet needs in cancer supportive care.
This article is based on a press release statement from Jaguar Health, Inc.
In other recent news, Jaguar Health reported a significant revenue increase for the fourth quarter of 2024, with net revenue rising by 53% compared to the same period in 2023. The company’s full-year revenue for 2024 grew by 20% year-over-year, reaching $11.7 million. This growth was attributed to increased prescription volumes of Mytesi and advancements in their product pipeline. Additionally, Jaguar Health completed a $3.4 million private placement through convertible promissory notes and unregistered warrants, with participation from key company executives and institutional investors. The funds raised are intended to support working capital and general corporate purposes.
Jaguar Health’s President and CEO, Lisa Conte, indicated that the capital is crucial for upcoming developments expected in the second quarter of 2025, particularly around the drug crofelemer. The company is optimistic about potential collaborations and licensing opportunities in the near future. H.C. Wainwright & Co. acted as the exclusive agent for the private placement. Despite reduced losses from operations, Jaguar Health continues to operate at a loss, which remains a challenge for the company. The company is also pursuing fast-track regulatory pathways, which can present unpredictability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.